MedTrace Logo

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

NCT00943072 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2013-05-27

Study results available
· View outcomes & findings →

Summary

This is a phase 3 study to determine the efficacy of VEGF Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion.

Conditions

  • Macular Edema Secondary to Central Retinal Vein Occlusion

Interventions

BIOLOGICAL

VEGF Trap-Eye 2.0mg

Monthly intravitreal injection out to the Week 24 Primary endpoint

DRUG

Sham

Monthly sham intravitreal injection out to Week 24 Primary Endpoint

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-10-31
Completion
2012-04-30

Countries

  • United States
  • Canada
  • Colombia
  • India
  • Israel

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00943072 on ClinicalTrials.gov